AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22837545
Drug: Daily life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily life activities (Control)
Trial: 29540336
Drug: Ilaparazole 10
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaparazole 10 mg QD
Trial: 29540336
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg QD
Trial: 25005651
Drug: Postoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotic treatment with amoxicillin plus clavulanic acid (2 g, 3 times a day for 5 days)
Trial: 25005651
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative antibiotics (nontreatment group)
Trial: 25005651
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (antibiotic and nontreatment)
Trial: 17974932
Drug: Self-management cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management cognitive behavior therapy
Trial: 16387596
Drug: Omalizumab (0.016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (0.016 mg/kg/IgE [IU/mL]/mo) plus immunotherapy
Trial: 16387596
Drug: Omalizumab plus
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Omalizumab plus immunotherapy
Trial: 16387596
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus immunotherapy
Trial: 31061282
Drug: Na restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na restriction (NaCl: 6 g/d)
Trial: 31061282
Drug: Control (NaCl:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (NaCl: 12 g/d)
Trial: 23912197
Drug: Dry needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry needling combined with autologous conditioned plasma (ACP) injection
Trial: 12078910
Drug: Early complete
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early complete response (ECR) patients after initial cycles of chemotherapy
Trial: 12078910
Drug: Shortened treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shortened treatment in ECR patients (randomized Swedish trial)
Trial: 12078910
Drug: Anthracyclines plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracyclines plus alkylating agents in children who failed to reach ECR (French MDH 90 trial)
Trial: 9621488
Drug: Carboplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (100 mg/m2 at 7 and 21 days) with 148 MBq 89Sr
Trial: 9621488
Drug: Cisplatin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (50 mg/m2 in two administrations) with 148 MBq 89Sr
Trial: 62265
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (MOPP: mustine hydrochloride, vincristine, procarbazine, and prednisone)
Trial: 62265
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (MOPP)
Trial: 11137283
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ritanserin for 4 weeks
Trial: 9392620
Drug: Continuous-infusion BSO
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion BSO alone
Trial: 9392620
Drug: BSO plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSO plus melphalan (15 mg/m2)
Trial: 7639365
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fentanyl and clonidine
Trial: 21154196
Drug: Oxytocin (OT)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin (OT) infused at a constant rate of 2 mIU/ml from -15 to 60 min before insulin administration
Trial: 14564551
Drug: Modified angiographic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified angiographic protocol (127 patients); 20 mL iodinated contrast, digital subtraction fluoroscopy for 60 sec.
Trial: 10625720
Drug: Clomethiazole (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomethiazole (75 mg/kg intravenous infusion for 24 hours)
Trial: 1590670
Drug: Oral riboflavin
RxNorm normalized name: riboflavin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral riboflavin therapy
Trial: 2859871
Drug: Adimolol 25
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adimolol 25 mg
Trial: 2859871
Drug: Adimolol 600
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adimolol 600 mg
Trial: 2859871
Drug: Adimolol 400
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adimolol 400 mg
Trial: 2859871
Drug: Labetalol 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol 800 mg
Trial: 29678756
Drug: D&C plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D&C plus NCH gel application (NCH gel group)
Trial: 27626473
Drug: LDE-paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE-paclitaxel (175 mg/m2, intravenous administration, 3/3 weeks for 6 cycles)
Trial: 25197811
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg) in the morning
Trial: 25197811
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg) in the evening
Trial: 17664376
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 or 40 mg, depending on age, continued after a previous placebo-controlled study for an average treatment period of 4.5 years.
Trial: 16236186
Drug: Haem iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haem iron preparation
Trial: 12473512
Drug: Novel oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel oral therapies
Trial: 10209080
Drug: Ephedrine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (50 mg thrice daily)
Trial: 7609291
Drug: Rectal diclofenac
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diclofenac 50 mg plus continuous epidural infusion with buprenorphine and bupivacaine
Trial: 7609291
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural infusion with buprenorphine and bupivacaine
Trial: 318971
Drug: Fosfomycin 2
RxNorm normalized name: fosfomycin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin 2 g daily in four divided doses for 28 days
Trial: 31021036
Drug: facilitated subcutaneous
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: facilitated subcutaneous immunoglobulin (fSCIG)
Trial: 31021036
Drug: conventional subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional subcutaneous immunoglobulin (cSCIG)
Trial: 27592520
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (listening to music three days a week for 8 weeks)
Trial: 21792546
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (control group) with monthly social work contact
Trial: 19873915
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Methycobal and Vitamin B1 (medication group)
Trial: 17878129
Drug: Breast Cancer
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast Cancer Education Intervention (BCEI) delivered in three face‐to‐face sessions and five monthly follow‐up sessions (three by telephone and two in person)
Trial: 17878129
Drug: Wait control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait control group receiving four monthly attention control telephone calls and the BCEI at month 6
Trial: 10690889
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment group A (4 IU/m2 x day)
Trial: 10690889
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment group B (4 IU/m2 x day for the first year, then 6 IU/m2 x day)
Trial: 10690889
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment group C (4 IU/m2 x day for the first year, 6 IU/m2 x day for the second year, then 8 IU/m2 x day)
Trial: 10690889
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment group C1 (7-year data from group C)
Trial: 10690889
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (mean duration 85.3 months)
Trial: 8360391
Drug: Anthelmintic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthelmintic treatment (Oxantel-Pyrantel; Quantrel) for 22 months
Trial: 8360391
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (children who declined treatment)
Trial: 2875439
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: no treatment
Trial: 20830502
Drug: Vandetanib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (100 mg once daily) plus docetaxel (100 mg/m² IV every 21 days)
Trial: 20830502
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus docetaxel (100 mg/m² IV every 21 days)
Trial: 19459523
Drug: Histamine-2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-2 receptor antagonists (H2RA)
Trial: 15562020
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg testosterone enanthate weekly
Trial: 15562020
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg testosterone enanthate weekly
Trial: 15562020
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg testosterone enanthate weekly
Trial: 15562020
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg testosterone enanthate weekly
Trial: 15562020
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg testosterone enanthate weekly
Trial: 12244484
Drug: Medium-molecular-weight heparin
RxNorm normalized name: chitosan medium molecular weight (200-800 MPA.S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-molecular-weight heparin (MMWH)
Trial: 10443094
Drug: Xylocaine injection
RxNorm normalized name: Xylocaine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylocaine injection at the gastrocnemius trigger point (TrP)
Trial: 10443094
Drug: Oral quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quinine sulfate 300 mg
Trial: 7603215
Drug: Ganciclovir (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir (6 mg/kg body weight per day intravenously from postoperative day 1 to day 30, then 6 mg/kg per day Monday through Friday until day 100)
Trial: 7603215
Drug: Acyclovir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (10 mg/kg intravenously every 8 h from postoperative day 1 to day of discharge, then 800 mg orally four times a day until day 100)
Trial: 1695049
Drug: Cisplatin (DDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (DDP) in combination with Adriamycine (ADM) and Cyclophosphamid (CTX)
Trial: 23786282
Drug: SIT (Specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIT (Specific Immunotherapy)
Trial: 15531661
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of plant sterols and exercise
Trial: 9272403
Drug: Moxonidine 0.4
RxNorm normalized name: moxonidine 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.4 mg once daily with lorazepam
Trial: 23665885
Drug: Heparin filling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin filling
Trial: 22172428
Drug: Gold kiwifruit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold kiwifruit (4 kiwifruit daily)
Trial: 22172428
Drug: Banana (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Banana (2 bananas daily)
Trial: 20420510
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alfa-2a (180 microg weekly for 12 weeks)
Trial: 17394626
Drug: Ibuprofen-foam dressing
RxNorm normalized name: ibuprofen Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen-foam dressing
Trial: 10988044
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g taken 30 min before HSG
Trial: 8841797
Drug: S-adenosylmethionine (SAMe)
RxNorm normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosylmethionine (SAMe) 1000 mg/day i.m.
Trial: 8841797
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 450 mg/day
Trial: 6715724
Drug: Flurbiprofen, 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen, 75 mg
Trial: 6715724
Drug: Chlorpheniramine, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine, 6 mg
Trial: 31791370
Drug: Healthy lifestyle
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy lifestyle modification based on traditional Chinese medicine (TCM)
Trial: 28167156
Drug: Eluxadoline 75
RxNorm normalized name: eluxadoline 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eluxadoline 75 mg
Trial: 15337695
Drug: Nesiritide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesiritide (2 microg/kg IV bolus followed by an infusion of 0.01 microg/kg per minute)
Trial: 9257066
Drug: Different radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different radiation doses
Trial: 8329252
Drug: Nasal administration
RxNorm normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal administration of midazolam 0.2 mg kg‐1
Trial: 8329252
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of midazolam 0.2 mg kg‐1
Trial: 8329252
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of midazolam 0.2 mg kg‐1
Trial: 3518624
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (2.1 g/day on a twice‐daily regimen)
Trial: 3518624
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (1.05 g/day on a twice‐daily regimen)
Trial: 3518624
Drug: Bismuth subsalicylate
RxNorm normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subsalicylate (active medication)
Trial: 27655538
Drug: Zinc supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplement (zinc gluconate granules for 10 days)
Trial: 20604703
Drug: Extended cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended cognitive behavior therapy for cigarette smoking cessation
Trial: 20604703
Drug: Model 1
RxNorm normalized name: Model AA 2012 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model 1 (pretreatment factors, demographic characteristics, treatment assignment)
Trial: 20604703
Drug: Model 2
RxNorm normalized name: Model 2004FAA Model 3-EEMK Model 3-EEMK-1 Model AA-8565 Model AA-8565-LATAM Model AWFAREMK Model CHAUTAUQUAEMK Model emk1000-10 Model FAREMK Model PMONTFAREMK Model SWEEMK Model SWEEMK-1 Model QXEMK Model G4FAREMK Model AA-8565 (excluding Miami Air) KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model 2 (Model 1 variables + clinical data during treatment)
Trial: 9691858
Drug: midazolam 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.03 mg kg‐1 i.v.
Trial: 9691858
Drug: midazolam 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.06 mg kg‐1 i.v.
Trial: 25385878
Drug: Nicotine inhaler
RxNorm normalized name: nicotine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine inhaler device (0.22 mg, 0.45 mg, 0.67 mg doses)
Trial: 25385878
Drug: Nicotine inhaler
RxNorm normalized name: nicotine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine inhaler device (0.67 mg repeated hourly for 12 hr)
Trial: 19487269
Drug: golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 50 or 100 mg every 2 or 4 weeks + MTX
Trial: 14769595
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of brimonidine and dorzolamide
Trial: 3907843
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg OD
Trial: 3907843
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg OD
Trial: 30001703
Drug: Positive STEPS
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Positive STEPS intervention (two-way daily text messaging as a reminder system, progressing to in-person counseling if needed)
Trial: 28956786
Drug: Liraglutide added
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide added to insulin for 26 weeks
Trial: 28956786
Drug: Liraglutide added
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide added to insulin for 8 weeks
Trial: 24490058
Drug: Glucomannan (1.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan (1.33 grams taken with 236.6 mL of water before meals)
Trial: 24490058
Drug: Placebo (identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identically looking capsules taken with 236.6 mL of water before meals)
Trial: 21996369
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methotrexate (HDM), n = 79
Trial: 11059442
Drug: Antidepressant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant therapy (including tricyclic antidepressants such as amitriptyline, clomipramine, desipramine, doxepin, trimipramine, and the antiserotonin agent mianserin)
Trial: 23471307
Drug: Prophylactic G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic G-CSF
Trial: 1736695
Drug: Intravenous diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diclofenac 75 mg loading dose followed by 5 mg/hour infusion
Trial: 3963154
Drug: Morphine and
RxNorm normalized name: morphine and antispasmodics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine and glycopyrrolate
Trial: 31542446
Drug: Customized Consumer
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized Consumer Medication Information (C-CMI)
Trial: 23948349
Drug: Dose-dense treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense treatment (carboplatin AUC 6 mg/mL per min on day 1 and paclitaxel 80 mg/m2 on days 1, 8, and 15)
Trial: 23948349
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (carboplatin AUC 6 mg/mL per min and paclitaxel 180 mg/m2 on day 1)
Trial: 20104529
Drug: Control (azulene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (azulene oral rinse)
Trial: 16807754
Drug: Dyed test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dyed test formulation administered intranasally
Trial: 16807754
Drug: Lateral head
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral head position during administration
Trial: 14682142
Drug: Accelerated hyperfractionation
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionation (AHF) 1.3 Gy, twice a day, 5 weeks, total 57.2-70 Gy
Trial: 8615463
Drug: thigh-high, vinyl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thigh-high, vinyl, sequential-pulse IPC system